Sinopharm A-Think Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") is a secondary subsidiary company of Sinopharm Group Co., Ltd., which is a professional and high-growth mixed-ownership pharmaceutical enterprise integrating R&D, production and marketing. The company founded in
1997 is located in Changchun City, Jilin Province, with the registered capital of 100 million RMB, covers an area of about 125,000 m2, and has more than 600 employees. In 2008, the company was rated as state-level high-tech enterprise, and became the only professional anti-cancer pharmaceutical platform affiliated to China National Pharmaceutical Group and Sinopharm Group.
The production base located in Shuangyang Economic Development Zone; the main product Mannatide for Injection (Lifein) is the founder of domestic mannatide brand; the patented product Octreotide Acetate Injection (Lierning) sales the best in nationalwide market. The freeze-dried power injection (including antineoplastic agents) and small volume injections all passed through the new version of GMP certification and obtained GMP certificate in 2013; the tablet (including antineoplastic agents) and hard capsules passed through the GMP on-site inspection and obtained certification in 2016.
The company has domestic advanced research and development laboratory and pilot workshop, core research team of more than 40 people which includes 70% doctoral and master's degree researchers, and overseas Chinese scientists and long-term cooperation experts advisory team of more than 10 people expertise in drug chemistry, pharmacy, drug synthesis, drug analysis, pharmacology and biomedical, clinical and other fields. The company has successfully developed more than 30 projects, with more than 20 independent intellectual property rights, and at this stage there are a total of more than 30 projects in research and technological transformation.
The company adopts the marketing model of lean investment attraction under the academic support, takes the compliance operation and control as the premise, uses comprehensive budget and performance management tools, and improves the product market coverage and market share through
customer upgrades and academic support. The company has a sales team now up to 170 people, forming 29 provinces of nationwide coverage of sales network, and covering more than 1,600 stable customers, 3500 hospital sale terminals, among which 930 hospitals are the third-tier hospitals.
The company has a solid quality management system, to strictly control each link of drug research and development, production and sales. The company always complies with the practices of pharmaceutical industry, adhering to quality policy of “care for life, care for health; quality first; rigorous attitude, sound system, security protection; continuous improvement to satisfy customer”, and continuously improving the quality of drugs, to ensure the safety of the public medication by using the most stringent standards with the most stringent attitude.
Sinopharm A-Think will uphold the "care for life, care for health" cooperate philosophy, to create a new product portfolio at international level that leads in domestic and meets future strategic objectives in terms of new drug development such as anti-tumor and antiviral drugs. And through endogeny and extension combination of development strategy, it will gradually develop into an integrated service provider of prevention, diagnosis, treatment, rehabilitation and health care.